Skip to main content
Erschienen in: Pediatric Nephrology 4/2015

01.04.2015 | Original Article

Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort

verfasst von: Meredith A. Atkinson, Ji Young Kim, Cindy N. Roy, Bradley A. Warady, Colin T. White, Susan L. Furth

Erschienen in: Pediatric Nephrology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepcidin, a key iron regulatory protein, is elevated in patients with chronic kidney disease (CKD). Its role in the development and progression of the anemia of CKD in children remains poorly defined.

Methods

Cross-sectional and longitudinal study in children aged 1–16 years with stage 2–4 CKD in the Chronic Kidney Disease in Children (CKiD) cohort (n = 133) with hepcidin measured at baseline and hemoglobin (HGB) measured annually at follow-up. Anemia was defined as HGB <5th percentile for age/sex OR treatment with an erythropoiesis-stimulating agent (ESA).

Results

Hepcidin levels correlated negatively with glomerular filtration rate (GFR; r = −0.22, p = 0.01) and positively with ferritin (r = 0.67, p < 0.001). At the lower end of the GFR spectrum at baseline (10th percentile, 27.5 mL/min/1.73 m2), higher hepcidin was associated with a 0.87 g/dL decrease in HGB during follow-up (95 % CI −1.69, −0.05 g/dL, p = 0.038). At higher GFR percentiles there was no significant association between baseline hepcidin and HGB during follow-up. Among 90 non-anemic subjects at baseline, 23.3 % developed incident anemia. In subjects with GFR ≤ the median, a higher hepcidin level was associated with an increased risk of incident anemia (at the 10th percentile GFR, HR 3.471, 95 % CI 1.228, 9.810, p = 0.019; at the 25th percentile GFR, HR 2.641, 95 % CI 1.213, 5.750, p = 0.014; at the 50th percentile GFR, HR 1.953, 95 % CI 1.011, 3.772, p = 0.046). Among subjects with GFR at the 75th percentile or above, incrementally higher baseline hepcidin was not associated with increased anemia risk.

Conclusions

Higher hepcidin levels are associated with a decreased HGB and an increased risk of incident anemia, and this association is most significant among subjects with lower GFR.
Literatur
1.
Zurück zum Zitat Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P (2014) Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol 5(86):1–13 Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P (2014) Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol 5(86):1–13
2.
Zurück zum Zitat Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. J Clin Invest 306(5704):2090–2093 Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. J Clin Invest 306(5704):2090–2093
3.
Zurück zum Zitat Roy CN, Andrews NC (2005) Anemia of inflammation: the hepcidin link. Curr Opin Hematol 12(2):107–111CrossRefPubMed Roy CN, Andrews NC (2005) Anemia of inflammation: the hepcidin link. Curr Opin Hematol 12(2):107–111CrossRefPubMed
4.
Zurück zum Zitat Atkinson MA, White CT (2012) Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 27(1):33–40CrossRefPubMed Atkinson MA, White CT (2012) Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 27(1):33–40CrossRefPubMed
5.
6.
Zurück zum Zitat Coyne DW (2011) Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 80(3):240–244CrossRefPubMed Coyne DW (2011) Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 80(3):240–244CrossRefPubMed
7.
Zurück zum Zitat Niihata K, Tomosugi N, Uehata T, Shoji T, Mitsumoto K, Shimizu M, Kawabata H, Sakaguchi Y, Suzuki A, Hayashi T, Okada N, Isaka Y, Rakugi H, Tsubakihara Y (2012) Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease. Nephrol Dial Transplant 27(12):4378–4385, discussion 4384–4385CrossRefPubMed Niihata K, Tomosugi N, Uehata T, Shoji T, Mitsumoto K, Shimizu M, Kawabata H, Sakaguchi Y, Suzuki A, Hayashi T, Okada N, Isaka Y, Rakugi H, Tsubakihara Y (2012) Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease. Nephrol Dial Transplant 27(12):4378–4385, discussion 4384–4385CrossRefPubMed
8.
Zurück zum Zitat Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB (2009) Hepcidin–a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4(6):1051–1056CrossRefPubMedCentralPubMed Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB (2009) Hepcidin–a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4(6):1051–1056CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB (2010) Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 5(6):1010–1014CrossRefPubMedCentralPubMed Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB (2010) Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 5(6):1010–1014CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75(9):976–981CrossRefPubMed Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75(9):976–981CrossRefPubMed
12.
Zurück zum Zitat Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M (2006) Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am J Hematol 81(11):832–837CrossRefPubMed Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M (2006) Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am J Hematol 81(11):832–837CrossRefPubMed
13.
Zurück zum Zitat Mercadel L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B, the NephroTest Study Group (2014) The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 9(6):e99781CrossRefPubMedCentralPubMed Mercadel L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B, the NephroTest Study Group (2014) The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 9(6):e99781CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M (2014) Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol 25:564–572CrossRefPubMed Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M (2014) Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol 25:564–572CrossRefPubMed
15.
16.
Zurück zum Zitat Malyszko J, Mysliwiec M (2007) Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30(1):15–30CrossRefPubMed Malyszko J, Mysliwiec M (2007) Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30(1):15–30CrossRefPubMed
17.
Zurück zum Zitat Abraham AG, Mak RH, Mitsnefes M, White C, Moxey-Mims M, Warady B, Furth SL (2014) Protein energy wasting in children with chronic kidney disease. Pediatr Nephrol 29(7):1231–1238CrossRefPubMed Abraham AG, Mak RH, Mitsnefes M, White C, Moxey-Mims M, Warady B, Furth SL (2014) Protein energy wasting in children with chronic kidney disease. Pediatr Nephrol 29(7):1231–1238CrossRefPubMed
18.
Zurück zum Zitat Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Munoz A, Warady BA (2006) Design and methods of the chronic kidney disease in children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 1(5):1006–1015CrossRefPubMedCentralPubMed Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Munoz A, Warady BA (2006) Design and methods of the chronic kidney disease in children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 1(5):1006–1015CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58(2):259–263PubMed Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58(2):259–263PubMed
20.
Zurück zum Zitat Fadrowski JJ, Pierce CB, Cole SR, Moxey-Mims M, Warady BA, Furth SL (2008) Hemoglobin decline in children with chronic kidney disease: Baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol 3(2):457–462CrossRefPubMedCentralPubMed Fadrowski JJ, Pierce CB, Cole SR, Moxey-Mims M, Warady BA, Furth SL (2008) Hemoglobin decline in children with chronic kidney disease: Baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol 3(2):457–462CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279–335CrossRef Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279–335CrossRef
22.
Zurück zum Zitat Hollowell JG, van Assendelft OW, Gunter EW, Lewis BG, Naijar M, Pfeiffer C (2005) Hematological and iron-related analytes—reference data for persons aged 1 year and over: United States, 1988–94. Vital Health Stat 11 (247):1–156 Hollowell JG, van Assendelft OW, Gunter EW, Lewis BG, Naijar M, Pfeiffer C (2005) Hematological and iron-related analytes—reference data for persons aged 1 year and over: United States, 1988–94. Vital Health Stat 11 (247):1–156
23.
Zurück zum Zitat Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M (2008) Immunoassay for human serum hepcidin. Blood 112(10):4292–4297CrossRefPubMed Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M (2008) Immunoassay for human serum hepcidin. Blood 112(10):4292–4297CrossRefPubMed
24.
Zurück zum Zitat Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629–637CrossRefPubMedCentralPubMed Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629–637CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, Kaskel F, Furth SL, Schwartz GJ, CKiD Investigators (2009) Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol 4(4):812–819CrossRefPubMedCentralPubMed Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, Kaskel F, Furth SL, Schwartz GJ, CKiD Investigators (2009) Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol 4(4):812–819CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S (2006) Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 17(10):2878–2885CrossRefPubMed Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S (2006) Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 17(10):2878–2885CrossRefPubMed
27.
Zurück zum Zitat Borzych-Duzalka D, Bilginer Y, Ha IS, Bak M, Rees L, Cano F, Munarriz RL, Chua A, Pesle S, Emre S, Urzykowska A, Quiroz L, Ruscasso JD, White C, Pape L, Ramela V, Printza N, Vogel A, Kuzmanovska D, Simkova E, Muller-Wiefel DE, Sander A, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network (IPPN) Registry (2013) Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24(4):665–676CrossRefPubMedCentralPubMed Borzych-Duzalka D, Bilginer Y, Ha IS, Bak M, Rees L, Cano F, Munarriz RL, Chua A, Pesle S, Emre S, Urzykowska A, Quiroz L, Ruscasso JD, White C, Pape L, Ramela V, Printza N, Vogel A, Kuzmanovska D, Simkova E, Muller-Wiefel DE, Sander A, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network (IPPN) Registry (2013) Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24(4):665–676CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Atkinson MA, Martz K, Warady BA, Neu AM (2010) Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 25(9):1699–1706CrossRefPubMed Atkinson MA, Martz K, Warady BA, Neu AM (2010) Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 25(9):1699–1706CrossRefPubMed
29.
Zurück zum Zitat Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, Kaneko T, Okada N, Yamamoto R, Nagasawa Y, Kato K, Isaka Y, Rakugi H, Tsubakihara Y (2012) Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant 27(3):1076–1083CrossRefPubMed Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, Kaneko T, Okada N, Yamamoto R, Nagasawa Y, Kato K, Isaka Y, Rakugi H, Tsubakihara Y (2012) Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant 27(3):1076–1083CrossRefPubMed
30.
Zurück zum Zitat Macdougall IC, Malyszko J, Hider RC, Bansal SS (2010) Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 5(9):1681–1689CrossRefPubMed Macdougall IC, Malyszko J, Hider RC, Bansal SS (2010) Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 5(9):1681–1689CrossRefPubMed
31.
Zurück zum Zitat Cangemi G, Pistorio A, Miano M, Gattorno M, Acquila M, Bicocchi MP, Gastaldi R, Riccardi F, Gatti C, Fioredda F, Calvillo M, Melioli G, Martini A, Dufour C (2013) Diagnostic potential of hepcidin testing in pediatrics. Eur J Haematol 90(4):323–330CrossRefPubMed Cangemi G, Pistorio A, Miano M, Gattorno M, Acquila M, Bicocchi MP, Gastaldi R, Riccardi F, Gatti C, Fioredda F, Calvillo M, Melioli G, Martini A, Dufour C (2013) Diagnostic potential of hepcidin testing in pediatrics. Eur J Haematol 90(4):323–330CrossRefPubMed
32.
Zurück zum Zitat Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, vanTienoven D, Wetzels JFM, Kiemeney LALM, Sweep F, den Heijer M, Swinkels DW (2011) Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 117(25):e218–e225CrossRefPubMed Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, vanTienoven D, Wetzels JFM, Kiemeney LALM, Sweep F, den Heijer M, Swinkels DW (2011) Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 117(25):e218–e225CrossRefPubMed
33.
Zurück zum Zitat Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113(9):1271–1276CrossRefPubMedCentralPubMed Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113(9):1271–1276CrossRefPubMedCentralPubMed
34.
Zurück zum Zitat Atkinson MA, Pierce CB, Fadrowski JJ, Benador NM, White CT, Turman MA, Pan CG, Abraham AG, Warady BA, Furth SL (2012) Association between common iron store markers and hemoglobin in children with chronic kidney disease. Pediatr Nephrol 27(12):2275–2283CrossRefPubMedCentralPubMed Atkinson MA, Pierce CB, Fadrowski JJ, Benador NM, White CT, Turman MA, Pan CG, Abraham AG, Warady BA, Furth SL (2012) Association between common iron store markers and hemoglobin in children with chronic kidney disease. Pediatr Nephrol 27(12):2275–2283CrossRefPubMedCentralPubMed
35.
Zurück zum Zitat Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, Investigators CHOIR (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355(20):2085–2098CrossRefPubMed Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, Investigators CHOIR (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355(20):2085–2098CrossRefPubMed
36.
Zurück zum Zitat Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019–2032CrossRefPubMed Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019–2032CrossRefPubMed
37.
Zurück zum Zitat Lestz RM, Fivush BA, Atkinson MA (2014) Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 29(10):2021–2028CrossRefPubMed Lestz RM, Fivush BA, Atkinson MA (2014) Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 29(10):2021–2028CrossRefPubMed
38.
Zurück zum Zitat Stancu S, Barsan L, Stanciu A, Mircescu G (2010) Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 5(3):409–416CrossRefPubMedCentralPubMed Stancu S, Barsan L, Stanciu A, Mircescu G (2010) Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 5(3):409–416CrossRefPubMedCentralPubMed
40.
Zurück zum Zitat Ruchala P, Nemeth E (2014) The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci 35(3):155–161CrossRefPubMed Ruchala P, Nemeth E (2014) The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci 35(3):155–161CrossRefPubMed
41.
Zurück zum Zitat Sun CC, Vaja V, Babitt JL, Lin HY (2012) Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 87(4):392–400CrossRefPubMedCentralPubMed Sun CC, Vaja V, Babitt JL, Lin HY (2012) Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 87(4):392–400CrossRefPubMedCentralPubMed
42.
Zurück zum Zitat Schwartz GJ, Furth S, Cole SR, Warady B, Munoz A (2006) Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int 69(11):2070–2077CrossRefPubMed Schwartz GJ, Furth S, Cole SR, Warady B, Munoz A (2006) Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int 69(11):2070–2077CrossRefPubMed
43.
Zurück zum Zitat Ford BA, Eby CS, Scott MG, Coyne DW (2010) Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 78(8):769–773CrossRefPubMed Ford BA, Eby CS, Scott MG, Coyne DW (2010) Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 78(8):769–773CrossRefPubMed
Metadaten
Titel
Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort
verfasst von
Meredith A. Atkinson
Ji Young Kim
Cindy N. Roy
Bradley A. Warady
Colin T. White
Susan L. Furth
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 4/2015
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-014-2991-4

Weitere Artikel der Ausgabe 4/2015

Pediatric Nephrology 4/2015 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.